These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

66 related articles for article (PubMed ID: 28964575)

  • 21. Evaluation of the Expression of Amine Oxidase Proteins in Breast Cancer.
    Sun WY; Choi J; Cha YJ; Koo JS
    Int J Mol Sci; 2017 Dec; 18(12):. PubMed ID: 29261141
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Expression of matrix metalloproteinases and their inhibitors in different immunohistochemical-based molecular subtypes of breast cancer.
    Kim GE; Lee JS; Choi YD; Lee KH; Lee JH; Nam JH; Choi C; Kim SS; Park MH; Yoon JH; Kweon SS
    BMC Cancer; 2014 Dec; 14():959. PubMed ID: 25510449
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Abundant NDRG2 Expression Is Associated with Aggressiveness and Unfavorable Patients' Outcome in Basal-Like Breast Cancer.
    Kloten V; Schlensog M; Eschenbruch J; Gasthaus J; Tiedemann J; Mijnes J; Heide T; Braunschweig T; Knüchel R; Dahl E
    PLoS One; 2016; 11(7):e0159073. PubMed ID: 27400234
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes.
    Carey LA; Dees EC; Sawyer L; Gatti L; Moore DT; Collichio F; Ollila DW; Sartor CI; Graham ML; Perou CM
    Clin Cancer Res; 2007 Apr; 13(8):2329-34. PubMed ID: 17438091
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Loss of breast cancer metastasis suppressor 1 protein expression predicts reduced disease-free survival in subsets of breast cancer patients.
    Hicks DG; Yoder BJ; Short S; Tarr S; Prescott N; Crowe JP; Dawson AE; Budd GT; Sizemore S; Cicek M; Choueiri TK; Tubbs RR; Gaile D; Nowak N; Accavitti-Loper MA; Frost AR; Welch DR; Casey G
    Clin Cancer Res; 2006 Nov; 12(22):6702-8. PubMed ID: 17121889
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Relationship of c-FLIP(L) protein expression with molecular subtyping and clinical prognosis in invasive breast cancer].
    Zang F; Wei X; Sun B
    Zhonghua Bing Li Xue Za Zhi; 2014 Jul; 43(7):442-6. PubMed ID: 25327791
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Breast cancer subtype approximated by estrogen receptor, progesterone receptor, and HER-2 is associated with local and distant recurrence after breast-conserving therapy.
    Nguyen PL; Taghian AG; Katz MS; Niemierko A; Abi Raad RF; Boon WL; Bellon JR; Wong JS; Smith BL; Harris JR
    J Clin Oncol; 2008 May; 26(14):2373-8. PubMed ID: 18413639
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Variations in tumor marker levels in metastatic breast cancer patients according to tumor subtypes.
    Kos T; Aksoy S; Sendur MA; Arik Z; Civelek B; Kandemir N; Ozdemir NY; Zengin N; Altundag K
    J BUON; 2013; 18(3):608-13. PubMed ID: 24065471
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Molecular subtypes of breast cancer in South Asian population by immunohistochemical profile and Her2neu gene amplification by FISH technique: association with other clinicopathologic parameters.
    Hashmi AA; Edhi MM; Naqvi H; Khurshid A; Faridi N
    Breast J; 2014; 20(6):578-85. PubMed ID: 25219294
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A retrospective study of breast cancer subtypes: the risk of relapse and the relations with treatments.
    Wang Y; Yin Q; Yu Q; Zhang J; Liu Z; Wang S; Lv S; Niu Y
    Breast Cancer Res Treat; 2011 Nov; 130(2):489-98. PubMed ID: 21837481
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Triple-negative phenotype is of adverse prognostic value in patients treated with dose-dense sequential adjuvant chemotherapy: a translational research analysis in the context of a Hellenic Cooperative Oncology Group (HeCOG) randomized phase III trial.
    Skarlos P; Christodoulou C; Kalogeras KT; Eleftheraki AG; Bobos M; Batistatou A; Valavanis C; Tzaida O; Timotheadou E; Kronenwett R; Wirtz RM; Kostopoulos I; Televantou D; Koutselini E; Papaspirou I; Papadimitriou CA; Pectasides D; Gogas H; Aravantinos G; Pavlidis N; Arapantoni P; Skarlos DV; Fountzilas G
    Cancer Chemother Pharmacol; 2012 Feb; 69(2):533-46. PubMed ID: 21901395
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Expression patterns of ER-alpha, PR, HER-2/neu, and EGFR in different cell origin subtypes of high grade and non-high grade ductal carcinoma in situ.
    Tang P; Wang X; Schiffhauer L; Wang J; Bourne P; Yang Q; Quinn A; Hajdu S
    Ann Clin Lab Sci; 2006; 36(2):137-43. PubMed ID: 16682508
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Metabolism-related proteins are differentially expressed according to the molecular subtype of invasive breast cancer defined by surrogate immunohistochemistry.
    Choi J; Jung WH; Koo JS
    Pathobiology; 2013; 80(1):41-52. PubMed ID: 22832328
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Identification of a basal-like subtype of breast ductal carcinoma in situ.
    Livasy CA; Perou CM; Karaca G; Cowan DW; Maia D; Jackson S; Tse CK; Nyante S; Millikan RC
    Hum Pathol; 2007 Feb; 38(2):197-204. PubMed ID: 17234468
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Assessment of HER-2 gene overexpression in Isfahan province breast cancer patients using Real Time RT-PCR and immunohistochemistry.
    Tabatabaeian H; Hojati Z
    Gene; 2013 Nov; 531(1):39-43. PubMed ID: 24013082
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Coupling proteomics and transcriptomics in the quest of subtype-specific proteins in breast cancer.
    Pavlou MP; Dimitromanolakis A; Diamandis EP
    Proteomics; 2013 Apr; 13(7):1083-95. PubMed ID: 23386393
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prognostic parameters of luminal A and luminal B intrinsic breast cancer subtypes of Pakistani patients.
    Hashmi AA; Aijaz S; Khan SM; Mahboob R; Irfan M; Zafar NI; Nisar M; Siddiqui M; Edhi MM; Faridi N; Khan A
    World J Surg Oncol; 2018 Jan; 16(1):1. PubMed ID: 29291744
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Young age at diagnosis correlates with worse prognosis and defines a subset of breast cancers with shared patterns of gene expression.
    Anders CK; Hsu DS; Broadwater G; Acharya CR; Foekens JA; Zhang Y; Wang Y; Marcom PK; Marks JR; Febbo PG; Nevins JR; Potti A; Blackwell KL
    J Clin Oncol; 2008 Jul; 26(20):3324-30. PubMed ID: 18612148
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Relationship between breast cancer molecular subtypes with clinicopathological characteristics and prognosis].
    Lin M; Chen ZQ; Bao Y; Li Q; Du ZG; Xu ZD; Tang F
    Zhonghua Bing Li Xue Za Zhi; 2010 Jun; 39(6):372-6. PubMed ID: 21055152
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Predictive role of molecular subtypes in response to neoadjuvant chemotherapy in breast cancer patients in Northeast China.
    Lv M; Li B; Li Y; Mao X; Yao F; Jin F
    Asian Pac J Cancer Prev; 2011; 12(9):2411-7. PubMed ID: 22296393
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.